The China National Medical Products Administration approved ivonescimab, in combination with pemetrexed and carboplatin for the treatment of patients with EGFR-mutated locally advanced or metastatic non-squamous NSCLC who have progressed after tyrosine kinase inhibitor therapy on May 23, 2024. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.